Researchers looked at how certain biomarkers might help predict how well patients with chronic rhinosinusitis with nasal polyps (CRSwNP) respond to treatment. The review analyzed data from 489 adults to see if eosinophil counts, which are a type of white blood cell, could indicate who might benefit most from medications like dupilumab, omalizumab, and anti-IL-5 agents.
The findings showed that patients with high eosinophil counts (over 300 cells per microliter) had significantly higher odds of improving their symptoms. These patients reported better scores on the SNOT-22 scale, which measures how symptoms affect daily life. The study also noted improvements in nasal polyp scores and radiologic scores for this group.
While the link between high eosinophils and better outcomes is clear in this data, it is important to note that no specific marker is currently validated for routine use in a doctor's office. This means the findings are currently used to understand the condition rather than as a standard tool for every patient. Talk with your doctor to see how these findings apply to your specific treatment plan.
